Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease

BACKGROUND AND AIMS: Circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) concentrations are related to the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, there are no data regarding the potential association between sTWEAK and atheromatosis progressio...

ver descrição completa

Detalhes bibliográficos
Autores: Fernández-Laso, V., Méndez-Barbero, Nerea, Valdivielso Revilla, José Manuel, Betriu i Bars, M. Àngels, Fernández i Giráldez, Elvira, Egido, Jesús, Martín-Ventura, JL., Blanco-Colio, LM.
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2017
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/63051
Acesso em linha:https://doi.org/10.1016/j.atherosclerosis.2017.03.043
http://hdl.handle.net/10459.1/63051
Access Level:Acceso aberto
Palavra-chave:Atherosclerosis
Progression
sTWEAK
Chronic kidney disease
id ES_cf98bf35279ed6d2e79d570d70029dd2
oai_identifier_str oai:recercat.cat:10459.1/63051
network_acronym_str ES
network_name_str España
repository_id_str
spelling Soluble TWEAK and atheromatosis progression in patients with chronic kidney diseaseSoluble TWEAK as a predictor of atheromatosis progression in patients with chronic kidney diseaseFernández-Laso, V.Méndez-Barbero, NereaValdivielso Revilla, José ManuelBetriu i Bars, M. ÀngelsFernández i Giráldez, ElviraEgido, JesúsMartín-Ventura, JL.Blanco-Colio, LM.AtherosclerosisProgressionsTWEAKChronic kidney diseaseBACKGROUND AND AIMS: Circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) concentrations are related to the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, there are no data regarding the potential association between sTWEAK and atheromatosis progression in patients free of cardiovascular events. METHODS: Soluble TWEAK serum concentration was measured in 702 CKD patients without any previous CV event from The National Observatory of Atherosclerosis in Nephrology (NEFRONA) Study. B-mode ultrasound was performed to detect the presence of carotid and/or femoral atherosclerotic plaques. The association between sTWEAK levels, atherosclerotic burden (number of plaques) and atheromatosis progression (increase in the number of plaques) after 24 months of follow-up was analyzed. RESULTS: A continuous decrease in sTWEAK concentrations, with an increase in the number of atherosclerotic plaques after 24 months of follow-up, was observed in the studied population. Multivariable linear regression analysis showed that age, blood pressure, HDL-c, and sTWEAK concentrations were independent predictors of atherosclerotic burden after 24 months of follow-up. In addition, sTWEAK concentrations diminished in CKD patients in whom progressive silent atherosclerosis was observed. Multivariable linear regression analysis showed that age, sex, smoking status and sTWEAK levels were independent predictors of atheromatosis progression after 24 months of follow-up. CONCLUSIONS: Lower sTWEAK concentrations are associated with atherosclerotic burden and atheromatosis progression in CKD patients free of clinical CVD. These data suggest that sTWEAK could serve as a biomarker to predict CV risk before clinical manifestations.This work was supported by Fondo de Investigaciones Sanitarias (Programa I3-SNS to LMBC), Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias ISCiii/FEDER PI13/00395, PI14/00384, PI16/01419, RETICS RD12/0042/0038) and Spanish Biomedical Research Centre in Cardiovascular Disease (CIBERCV) and in Diabetes and Associated Metabolic Disorders (CIBERDEM), Spain. The NEFRONA study is funded by a research grant from AbbVie and the Spanish goverment RETIC (RD12/0021/0026) and FIS PI13/01565Elsevier2018201820172018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://doi.org/10.1016/j.atherosclerosis.2017.03.043http://hdl.handle.net/10459.1/63051http://hdl.handle.net/10459.1/63051reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1016/j.atherosclerosis.2017.03.043Atherosclerosis, 2017, vol. 260, p. 130-137cc-by-nc-nd (c) Elsevier, 2017info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/oai:recercat.cat:10459.1/630512026-05-29T05:05:01Z
dc.title.none.fl_str_mv Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
Soluble TWEAK as a predictor of atheromatosis progression in patients with chronic kidney disease
title Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
spellingShingle Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
Fernández-Laso, V.
Atherosclerosis
Progression
sTWEAK
Chronic kidney disease
title_short Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
title_full Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
title_fullStr Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
title_full_unstemmed Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
title_sort Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
dc.creator.none.fl_str_mv Fernández-Laso, V.
Méndez-Barbero, Nerea
Valdivielso Revilla, José Manuel
Betriu i Bars, M. Àngels
Fernández i Giráldez, Elvira
Egido, Jesús
Martín-Ventura, JL.
Blanco-Colio, LM.
author Fernández-Laso, V.
author_facet Fernández-Laso, V.
Méndez-Barbero, Nerea
Valdivielso Revilla, José Manuel
Betriu i Bars, M. Àngels
Fernández i Giráldez, Elvira
Egido, Jesús
Martín-Ventura, JL.
Blanco-Colio, LM.
author_role author
author2 Méndez-Barbero, Nerea
Valdivielso Revilla, José Manuel
Betriu i Bars, M. Àngels
Fernández i Giráldez, Elvira
Egido, Jesús
Martín-Ventura, JL.
Blanco-Colio, LM.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Atherosclerosis
Progression
sTWEAK
Chronic kidney disease
topic Atherosclerosis
Progression
sTWEAK
Chronic kidney disease
description BACKGROUND AND AIMS: Circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) concentrations are related to the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, there are no data regarding the potential association between sTWEAK and atheromatosis progression in patients free of cardiovascular events. METHODS: Soluble TWEAK serum concentration was measured in 702 CKD patients without any previous CV event from The National Observatory of Atherosclerosis in Nephrology (NEFRONA) Study. B-mode ultrasound was performed to detect the presence of carotid and/or femoral atherosclerotic plaques. The association between sTWEAK levels, atherosclerotic burden (number of plaques) and atheromatosis progression (increase in the number of plaques) after 24 months of follow-up was analyzed. RESULTS: A continuous decrease in sTWEAK concentrations, with an increase in the number of atherosclerotic plaques after 24 months of follow-up, was observed in the studied population. Multivariable linear regression analysis showed that age, blood pressure, HDL-c, and sTWEAK concentrations were independent predictors of atherosclerotic burden after 24 months of follow-up. In addition, sTWEAK concentrations diminished in CKD patients in whom progressive silent atherosclerosis was observed. Multivariable linear regression analysis showed that age, sex, smoking status and sTWEAK levels were independent predictors of atheromatosis progression after 24 months of follow-up. CONCLUSIONS: Lower sTWEAK concentrations are associated with atherosclerotic burden and atheromatosis progression in CKD patients free of clinical CVD. These data suggest that sTWEAK could serve as a biomarker to predict CV risk before clinical manifestations.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1016/j.atherosclerosis.2017.03.043
http://hdl.handle.net/10459.1/63051
http://hdl.handle.net/10459.1/63051
url https://doi.org/10.1016/j.atherosclerosis.2017.03.043
http://hdl.handle.net/10459.1/63051
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1016/j.atherosclerosis.2017.03.043
Atherosclerosis, 2017, vol. 260, p. 130-137
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier, 2017
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier, 2017
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420097690402816
score 15.812429

Registros relacionados